HOUSTON: A treatment for leukaemia, nilotinib (Tasigna, Novartis), improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a Phase I clinical trial.
The researchers reported that the drug led to statistically significant and encouraging changes in toxic proteins linked to disease progression.